Science and Therapeutic Area
We aim to develop first-in-class and best-in-class macromolecular drugs through original innovation.
We have established a globally integrated R&D process. With four R&D centers worldwide, we have the outstanding ability to discover and develop innovative biologics. We are able to independently perform crucial procedures, i.e. target assessments, mechanism studies and validation, clinical drug screening and functional validation, etc.
US Innovation Center
San Francisco and Maryland laboratories focus on mechanistic studies of known and innovative targets, drug discovery, and precise screening of drug molecules in the field of oncology and autoimmune diseases.US laboratories closely follow the latest trends in biotechnological innovation and drug research and development.
China Innovation Center
Shanghai and Suzhou innovation centers mainly conduct the functional validation and process development of drugs.Chinese laboratories perform follow-up R&D work which enables efficient and economical R&D activities.
We have established an integrated technology system that covers the entire lifecycle of Protein drugs from early R&D all the way to industrialization.
Integrated technology system covering the entire lifecycleof Protein drugs from early R&D to industrialization
Automated High-efficiency Screening Platform for Antibody Selection and Functional Assays
Human Transmembrane Receptor Protein Array and High-throughput Screening Platform
High-yielding Stable Expression Cell Lines Screening and Establishment Platform
Antibody Quality Research, Control and Assurance Platform
Antibody Humanization and Construction Platform
CHO Cell Fermentation Process Development Platform
Antibody Purification Process Development and Formulation Optimization Platform
Antibody-Drug Conjugates Research and Development Platform
siRNA Drugs Research and Development Platform
Note:Company′s core technology platform
Our capacity for original innovation enables us to achieve new target discoveries and validation during the early stages of drug development, which means a higher level of drug research, a greater chance of drug discovery and success, and a wider range of diseases. As we continue to explore and validate more innovative targets, more and more drug candidates will enter our R&D pipeline, thus providing continuous innovation for our sustainable development.